BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2014 2:23:00 PM | Browse: 938 | Download: 790
Publication Name World Journal of Hepatology
Manuscript ID 7282
Country/Territory Italy
Received
2013-11-12 14:56
Peer-Review Started
2013-11-13 12:07
To Make the First Decision
2013-11-19 12:49
Return for Revision
2013-11-19 14:22
Revised
2014-01-07 03:06
Second Decision
2014-03-17 14:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-03-17 14:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-03-21 02:45
Typeset the Manuscript
2014-05-17 21:43
Publish the Manuscript Online
2014-05-27 11:34
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Genetics & Heredity
Manuscript Type Review
Article Title Chronic hepatitis B: advances in treatment
Manuscript Source Invited Manuscript
All Author List Teresa Antonia Santantonio and Massimo Fasano
Funding Agency and Grant Number
Corresponding Author Dr. Teresa Antonia Santantonio, Department of Clinical and Experimental Medicine, University of Foggia, Ospedali Riuniti, Viale Luigi Pinto 1, 71100 Foggia, Italy. teresa.santantonio@unifg.it
Key Words Chronic hepatitis; Antiviral therapy; Peg-interferon; Nucleos(t)ide analogues; Antiviral resistance
Core Tip Patients with chronic hepatitis B are a heterogeneous population and require different management strategies. In clinical practice, several baseline factors, related to the patient, drug, stage of liver disease, comorbidities, lifestyle factors, coinfections and profile of hepatitis B virus infection, should be taken into consideration in order to individually optimize therapy. Surface antigen of the hepatitis B virus quantification is a potential new biomarker for treatment individualization and response-guided therapy. In the last two decades, the availability of potent oral antivirals changed the natural history of chronic hepatitis B; however, the risk of hepatocellular carcinoma (HCC) has not been abolished and thus regular HCC surveillance in high risk patients is required.
Publish Date 2014-05-27 11:34
Citation Santantonio TA, Fasano M. Chronic hepatitis B: advances in treatment. World J Hepatol 2014; 6(5): 284-292
URL http://www.wjgnet.com/1948-5182/full/v6/i5/284.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i5.284
Full Article (PDF) WJH-6-284.pdf
Full Article (Word) WJH-6-284.doc
Manuscript File 7282-Review.doc
Answering Reviewers 7282-Answering reviewers.pdf
Copyright License Agreement 7282-Copyright assignment.pdf
Peer-review Report 7282-Peer reviews.pdf
Scientific Editor Work List 7282-Scientific editor work list.doc